HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Etifoxine analgesia in experimental monoarthritis: a combined action that protects spinal inhibition and limits central inflammatory processes.

Abstract
Inflammatory and degenerative diseases of the joint are major causes of chronic pain. Long-lasting pain symptoms are thought to result from a central sensitization of nociceptive circuits. These processes include activation of microglia and spinal disinhibition. Using a monoarthritic rat model of pain, we tried to potentiate neural inhibition by using etifoxine (EFX), a nonbenzodiazepine anxiolytic that acts as an allosteric-positive modulator of gamma-aminobutyric acid type A (GABAA) receptor function. Interestingly, EFX also can bind to the mitochondrial translocator protein (TSPO) complex and stimulate the synthesis of 3α-reduced neurosteroids, the most potent positive allosteric modulator of GABAA receptor function. Here we show that a curative and a preventive treatment with 50mg/kg of EFX efficiently reduced neuropathic pain symptoms. In the spinal cord, EFX analgesia was accompanied by a reduction in microglial activation and in the levels of proinflammatory mediators. Using electrophysiological tools, we found that EFX treatment not only amplified spinal GABAergic inhibition, but also prevented prostaglandin E2-induced glycinergic disinhibition and restored a "normal" spinal pain processing. Because EFX is already distributed in several countries under the trade name of Stresam for its anxiolytic actions in humans, new clinical trials are now required to further extend its therapeutic indications as pain killer.
AuthorsMaya Aouad, Vivien Zell, Pierre-Eric Juif, Adrien Lacaud, Yannick Goumon, Pascal Darbon, Vincent Lelievre, Pierrick Poisbeau
JournalPain (Pain) Vol. 155 Issue 2 Pg. 403-412 (Feb 2014) ISSN: 1872-6623 [Electronic] United States
PMID24239672 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Anti-Anxiety Agents
  • Inflammation Mediators
  • Oxazines
  • etifoxine
Topics
  • Animals
  • Anti-Anxiety Agents (pharmacology, therapeutic use)
  • Arthritis, Experimental (drug therapy, metabolism, pathology)
  • Inflammation (drug therapy, metabolism, pathology)
  • Inflammation Mediators (antagonists & inhibitors, metabolism)
  • Male
  • Neural Inhibition (drug effects, physiology)
  • Oxazines (pharmacology, therapeutic use)
  • Pain Management (methods)
  • Rats
  • Rats, Sprague-Dawley
  • Spinal Cord (drug effects, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: